The combination of PARPi (BMN673) (oral gavage, 0.33 mg/kg/day) and anti-PDL1 antibody (i.p., 200 μg/mouse, every 3 days) significantly mitigated the tumor burden in colorectal and ovarian syngeneic and nude mouse models [152]. Here, CD274 is linked to neoplasm.